In recent legal update, the Federal Circuit has directed the Patent Trial and Appeal Board (PTAB) to reevaluate a ruling related to Medtronic Inc.’s patents. This follows into the limelight, Axonics Inc.’s revived challenge against a pair of patents which Medtronic Inc. holds, surrounding its InterStim sacral stimulation system. This technological system is primarily used to treat control issues related to bladder and bowel.
The Federal Circuit has cited that the PTAB did not offer Axonics a fair opportunity to present a reply during a significant stage of the case. This pivotal moment could have potentially influenced the original decision taken against Axonics’ initial objection to these patents.
The PTAB will now need to reconsider its prior decision and reassess the arguments placed by Axonics, taking into consideration the company’s right to respond adequately at critical trial junctures.
The ongoing court case underlines the importance of providing both parties a fair and equal opportunity to present their respective cases throughout a dispute. As part of the corporate legal framework, this principle effectively upholds the values of justice and transparency, ensuring that the PTAB’s proceedings maintain integrity.
For further insights about this story, please visit
www.law360.com.